☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-bbb
Share this
PS Admin
Jun 20, 2024
Clinical Trials
Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-bbb
Click here
to read the full press release
Comments
Fill this Details
×
Name
Email
Company Name
Thank you for download PDF
Submit
Related News/Articles
Tubulis Reports the US FDA’s Fast Track Designation of TUB-040 to Treat Ovarian Cancer
June 28, 2024
Tubulis Reports the First Patient Dosing with TUB-040 in P-I/IIa Study to Treat Ovarian Cancer and Lung Adenocarcinoma-aa
June 20, 2024
PharmaShots Weekly Snapshots (September 23 – September 27, 2024)
September 27, 2024
Zoetis Collaborates with Danone to Develop Sustainable Practices in Dairy Farming Using Genetic Innovation
September 27, 2024
Orion and Aitia Join Forces for AI-Based Drug Discovery and Drug Simulation in Oncology
September 26, 2024
How Rising Drug Prices Affect Your Insurance
September 26, 2024
Insights+: EMA Marketing Authorization of New Drugs in August 2024
September 24, 2024
Generate:Biomedicines Partners with Novartis for the Discovery of Protein Therapeutics in Various Indications
September 24, 2024
Pharmaceutical Automation and Digitalisation Congress - AUTOMA+ 2024
September 23, 2024
The CHMP Grants Positive Opinion to Samsung Bioepis and Biogen’s Opuviz (Biosimilar, Eylea)
September 23, 2024
Liked our insights or summarized news?
Subscribe to our Daily/Weekly newsletter
×
First Name
Last Name
Daily Newsletter
Weekly Newsletter
I agree to the privacy policy and terms.(
Link
)
Stay Connected
LinkedIn
Twitter
Facebook
instagram
Youtube
Join the PharmaShots family of 12000+ subscribers
Newsletter
Subscribe Now
I accept the
Terms and Conditions
X
Liked our insights or summarized news?
Subscribe to our Daily/Weekly newsletter
Subscribe
Modal title
×
Modal body text goes here.